Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Celecoxib is a nonsteroidal anti-inflammatory drug
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Subscribe To Our Newsletter & Stay Updated